Show simple item record

dc.contributor.authorRiley, Margaret A.
dc.contributor.authorRobinson, Sandra M.
dc.contributor.authorRoy, Christopher M.
dc.contributor.authorDennis, Morgan
dc.contributor.authorLiu, Vivian
dc.contributor.authorDorit, Robert L.
dc.date2022-08-11T08:11:02.000
dc.date.accessioned2022-08-23T17:29:22Z
dc.date.available2022-08-23T17:29:22Z
dc.date.issued2012-12-01
dc.date.submitted2013-05-13
dc.identifier.citationBiochem Soc Trans. 2012 Dec 1;40(6):1438-42. doi: 10.1042/BST20120179.
dc.identifier.issn1470-8752
dc.identifier.doi10.1042/BST20120179.
dc.identifier.pmid23176495
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50302
dc.description.abstractPathogenic bacteria resistant to many or all antibiotics already exist. With the decline in microbiological research at pharmaceutical companies, the high rate at which resistance has evolved and spread has demanded a novel approach to addressing this critical human health issue. In the present paper, we propose a new paradigm in antibiotic discovery and development, one that applies ecological and evolutionary theory to design antimicrobial drugs that are more difficult and/or more costly to resist. In essence, we propose to simply adopt the strategies invented and applied by bacteria for hundreds of millions of years. Our research focuses on bacteriocins, powerful biological weapons, and their use as alternative therapeutics in human health.
dc.language.isoen_US
dc.publisherPortland Press On The Behalf Of The Biochemical Society
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23176495&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1042/BST20120179
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectBacteriuria
dc.subjectColicins
dc.subjectDrug Resistance, Bacterial
dc.subjectEscherichia coli
dc.subjectEscherichia coli Infections
dc.subjectHumans
dc.subjectMicrobial Sensitivity Tests
dc.subjectUMCCTS funding
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectBiochemistry, Biophysics, and Structural Biology
dc.subjectMicrobiology
dc.subjectTherapeutics
dc.titleResistance is futile: the bacteriocin model for addressing the antibiotic resistance challenge
dc.typeJournal Article
dc.source.journaltitleBiochemical Society transactions
dc.source.volume40
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/umccts_pubs/13
dc.identifier.contextkey4135651
html.description.abstract<p>Pathogenic bacteria resistant to many or all antibiotics already exist. With the decline in microbiological research at pharmaceutical companies, the high rate at which resistance has evolved and spread has demanded a novel approach to addressing this critical human health issue. In the present paper, we propose a new paradigm in antibiotic discovery and development, one that applies ecological and evolutionary theory to design antimicrobial drugs that are more difficult and/or more costly to resist. In essence, we propose to simply adopt the strategies invented and applied by bacteria for hundreds of millions of years. Our research focuses on bacteriocins, powerful biological weapons, and their use as alternative therapeutics in human health.</p>
dc.identifier.submissionpathumccts_pubs/13
dc.source.pages1438-42


This item appears in the following Collection(s)

Show simple item record